• 1
    Fausto N, Mead JE. Regulation of liver growth: protooncogenes and transforming growth factors. Lab Invest 1989; 60: 413.
  • 2
    Michalopoulos G. Liver regeneration: molecular mechanisms of growth control. FASEB J 1990; 4: 176187.
  • 3
    Steer CJ. Hepatic regeneration and growth regulation: therapeutic possibilities. In: AASLD Postgraduate Course; New and evolving therapies for hepatic and biliary diseases. St. Louis: Mosby-Year Book, 1993: 89112.
  • 4
    Derynck R. Transforming growth factor. Cell 1988; 54: 593595.
  • 5
    Massague J. Transforming growth factor-α: a model for membrane-anchored growth factors. J Biol Chem 1990; 265: 2139321396.
  • 6
    Marquardt H, Hunkapiller MW, Hood LE, Twardzik DR, De-Larco JE, Stephenson JR, Todaro GJ. Transforming growth factors produced by retrovirus-transformed rodent fibroblast and human melanoma cells: amino acid sequence homology with epidermal growth factor. Proc Natl Acad Sci U S A 1983; 80: 46844688.
  • 7
    Massague J. Epidermal growth factor-like transforming growth factor. II. Interaction with epidermal growth factor receptors on human placenta membrane and A431 cells. J Biol Chem 1983; 258: 1361413620.
  • 8
    Marquardt H, Hunkapiller MW, Hood LE, Todaro GJ. Rat transforming growth factor type I: tructure and relation to epidermal growth factor. Science 1984; 223: 10791082.
  • 9
    Mead JE, Fausto N. Transforming growth factor α may be a physiological regulator of liver regeneration by means of an auto-crine mechanism. Proc Natl Acad Sci U S A 1989; 86: 15581562.
  • 10
    Webber EM, Fitz Gerald MJ, Brown PI, Bartlett MH, Fausto N. Transforming growth factor-α expression during liver regeneration after partial hepatectomy and toxic injury, and potential interactions between transforming growth factor-α and hepato-cyte growth factor. Hepatology 1993; 18: 14221431.
  • 11
    Jhappan C, Stahle C, Harkins RN, Fausto N, Smith GH, Merlino GT. TGF α overexpression in transgenic mice induces liver neoplasia and abnormal development of the mammary gland and pancreas. Cell 1990; 61: 11371146.
  • 12
    Tomiya T, Fujiwara K. Serum levels of transforming growth factor-α in patients after partial hepatectomy as determined with an enzyme-linked immunosorbent assay. Hepatology 1993; 18: 304308.
  • 13
    Rusell WE, Dempsey PJ, Sitaric S, Peck AJ, Coffey RJ Jr. Transforming growth factor-α (TGFa) concentrations increase in regenerating rat liver: evidence for a delayed accumulation of murine TGFa. Endocrinology 1993; 133: 17311738.
  • 14
    Wolf HK, Michalopoulos GK. Hepatocyte regeneration in acute fulminant and nonfulminant hepatitis: a study of proliferating cell nuclear antigen expression. Hepatology 1992; 15: 707713.
  • 15
    O'Grady JG, Portmann B, Williams R. Fulminant hepatic failure. In: SchiffL, SchiffER, eds. Diseases of the liver. Vol 2, Ed 7. Philadelphia: Lippincott, 1993: 10771090.
  • 16
    Trey C, Lipworth L, Chalmers TC, Davidson CS, Gottlieb LS, Popper H, Saunders SJ. Fulminant hepatic failure: presumable contribution of halothane. N Engl J Med 1968; 279: 798801.
  • 17
    Horney JT, Galambos JT. The liver during and after fulminant hepatitis. Gastroenterology 1977; 73: 639645.
  • 18
    Tygstrup N. Fulminant hepatic failure. Semin Liver Dis 1986; 6: 137145.
  • 19
    Michalopoulos GK, Zarnegar R. Hepatocyte growth factor. Hepatology 1992; 15: 149155.
  • 20
    Ishiki Y, Ohnishi H, Muto Y, Matsumoto K, Nakamura T. Direct evidence that hepatocyte growth factor is a hepatotrophic factor for liver regeneration and has a potent antihepatitis effect in vivo. Hepatology 1992; 16: 12271235.
  • 21
    Fujiwara K, Nagoshi S, Ohno K, Hirata K, Ohta Y, Mochida S, Tomiya T et al. Stimulation of liver growth by exogeneous human hepatocyte growth factor in normal and partially hepatec-tomized rats. Hepatology 1993; 18: 14431449.
  • 22
    Fujiwara K, Ogata I, Sato Y, Tomiya T, Ohta Y, Oka Y, Nagoshi S et al. Insulin and glucagon therapy of acute hepatic failure. Dig Dis Sci 1991; 36: 809815.
  • 23
    Jaspan JB, Landau RL, Schneider J. Insulin and glucagon infusion in the treatment of liver failure. Arch Intern Med 1984; 144: 20752078.
  • 24
    Okita K, Masuda S, Hanta H, Yasunaga M, Sanuki K, Takemoto T. Clinical evaluation of glucagon and insulin in therapy of fulminant hepatic failure. Gastroenterol Jpn 1987; 22: 603613.
  • 25
    Fujiwara K, Ogata I, Oka H. Reciprocal changes in serum albumin and alpha-fetoprotein levels in the recovery course of acute viral hepatitis stimulated by glucagon and insulin therapy: analysis of a double blind control trial. Gastroenterol Jpn 1989; 24: 143148.
  • 26
    Oka H, Fujiwara K, Okita K, Ishii H, Sakuma A. A multi-centre double-blind controlled trial of glucagon and insulin therapy for severe acute hepatitis. Gastroenterol Jpn 1989; 24: 332336.
  • 27
    Baker AL, Jaspan JB, Haines NW, Hatfield GE, Krager PS, Schneider JF, The University of Chicago Medical House Staff. A randomized clinical trial of insulin and glucagon infusion for the treatment of alcoholic hepatitis: progress report in 50 patients. Gastroenterology 1981; 80: 14101414.
  • 28
    Feher J, Cornides A, Romany A, Karteszi M, Szalay L, Gogl A, Picazo J. A prospective multicenter study of insulin and glucagon therapy in acute alcoholic hepatitis. J Hepatol 1987; 5: 224231.
  • 29
    Takahashi Y. Acute hepatic failure—in special relation to treatment—. Jpn J Med 1983; 22: 140145.
  • 30
    Takahashi Y, Shimizu M. the study group of fulminant hepatitis. Aetiology and prognosis of fulminant viral hepatitis. J Gastroenterol Hepatol 1991; 6: 159164.
  • 31
    Takahashi Y, Kumada H, Shimizu M, Tanikawa K, Kumashiro R, Omata M, Ehata T, et al. A multicenter study on the prognosis of fulminant viral hepatitis: early prediction for liver transplantation. Hepatology 1994; 19: 10651071.
  • 32
    Trey C. Fulminant hepatitis surveillance study: brief review of the effects of presumed etiology and age on survival. Can Med Assoc J 1972; 106: 525527.
  • 33
    Tsubouchi H, Nitani Y, Hirono S, Nakayama H, Gohda E, Ara-kaki N, Sakiyama O et al. Levels of the human hepatocyte growth factor in serum of patients with various liver disease determined by an enzyme-linked immunosorbent assay. Hepatology 1991; 13: 15.
  • 34
    Tomiya T, Nagoshi S, Fujiwara K. Significance of serum human hepatocyte growth factor levels in patients with hepatic failure. Hepatology 1992; 15: 14.
  • 35
    Tomiya T, Tani M, Yamada S, Hayashi S, Umeda N, Fujiwara K. Serum hepatocyte growth factor levels in hepatectomized and nonhepatectomized surgical patients. Gastroenterology 1992; 103: 16211624.
  • 36
    Snedecor GW, Cochran WG. Statistical methods. Ed 7. Ames: The Iowa State University, 1980.
  • 37
    Kayano K, Yasunaga M, Kubota M, Takenaka K, Mori K, Yamashita A, Kubo Y et al. Detection of proliferating hepatocytes by immunohistochemical staining for proliferating cell nuclear antigen (PCNA) in patients with acute hepatic failure. Liver 1992; 12: 132136.
  • 38
    Kinoshita T, Hirao S, Matsumoto K, Nakamura T. Possible endocrine control by hepatocyte growth factor of liver regeneration after partial hepatectomy. Biochem Biophys Res Commun 1991; 177: 330335.
  • 39
    Matsumoto K, Nakamura T. Hepatocyte growth factor: molecular structure and implications for a central role in liver regeneration. J Gastroenterol Hepatol 1991; 6: 509519.
  • 40
    Nakayama H, Tsubouchi H, Gohda E, Koura M, Nagahama J, Yoshida H, Daikuhara Y et al. Stimulation of DNA synthesis in adult rat hepatocytes in primary culture by sera from patients with fulminant hepatic failure. Biomed Res 1985; 6: 231237.
  • 41
    Zarneger R, Michalopoulos G. Purification and biological characterization of human hepatopoietin A. a polypeptide growth factor for hepatocytes. Cancer Res 1989; 49: 33143320.
  • 42
    Takatsuki K, Fujiwara K, Hayashi S, Ohta Y, Torii M, Mishiro S, Ogata I et al. Acceleration of DNA synthesis in post-hepatec-tomized regenerating liver of normal rat by insulin and glucagon. Life Sci 1981; 29: 26092615.
  • 43
    Sato Y, Fujiwara K, Ogata I, Tomiya T, Oka H. Additive stimulation of hepatic putrescine production by glucagon and insulin after partial hepatectomy in rats. Life Sci 1989; 41: 7783.
  • 44
    Tomiya T, Sato Y, Murakami Y, Nagoshi S, Ogata I, Fujiwara K. Ornithine decarboxylase induction in partially hepatectomized rat liver and modes of its stimulation by glucagon and insulin. J Biochem 1991; 110: 173178.
  • 45
    Harrison PM, Hughes RD, Forbes A, Portmann B, Alexander GJM, Williams R. Failure of insulin and glucagon infusion to stimulate liver regeneration in fulminant hepatic failure. J Hepatol 1990; 10: 332336.
  • 46
    Woolf GM, Redeker AG. Treatment of fulminant hepatic failure with insulin and glucagon: a randomized controlled trial. Dig Dis Sci 1991; 36: 9296.